Silence Therapeutics PLC • SLN

Capital at risk.

About Silence Therapeutics PLC
Ticker
info
SLN
Trading on
info
NASDAQ
ISIN
info
US82686Q1013
Industry
info
Biotechnology
Sector
info
Healthcare
CEO
info
Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D
Headquarters
info
12 Hammersmith Grove, London, undefined, United Kingdom, W6 7AP
Employees
info
88
Website
info
silence-therapeutics.com
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Metrics
BasicAdvanced
Market cap
info
$919M
P/E ratio
info
-
EPS
info
-$1.30
Dividend Yield
info
0.00%
Beta
info
1.41
Forward P/E ratio
info
0
EBIDTA
info
$-63.9M
Ex dividend date
info
-
Price & volume
Market cap
info
$919M
Average daily volume
info
1.8M
90-day return
info
-
30-day return
info
-
7-day return
info
-
Dividends
Dividend per share
info
$0.00
Dividend yield
info
0.00%
Forward dividend per share
info
$0.00
Forward dividend yield
info
0.00%
Payout ratio
info
0.00%
Valuation
P/E ratio
info
0
Forward P/E
info
0
PEG ratio
info
-
Trailing P/E
info
0
Price to sales
info
1,494.73
Price to book
info
23.79
Earnings
EPS
info
-$1.30
EPS estimate (current quarter)
info
-$0.11
EPS estimate (next quarter)
info
-$0.10
EBITDA
info
$-63.9M
Revenues (TTM)
info
$0.6M
Revenues per share (TTM)
info
$0.01
Technicals
Beta
info
1.41
52-week High
info
$17.58
52-week Low
info
$4.19
50-day moving average
info
$11.70
200-day moving average
info
$7.56
Short ratio
info
1.51
Short %
info
4.81%
Management effectiveness
ROE (TTM)
info
-90.41%
ROA (TTM)
info
-29.65%
Profit margin
info
0.00%
Gross profit margin
info
$0.5M
Operating margin
info
-10,475.61%
Growth
Quarterly earnings growth (YoY)
info
0.00%
Quarterly revenue growth (YoY)
info
197.20%
Share stats
Outstanding Shares
info
62.2M
Float
info
37.8M
Insiders %
info
7.97%
Institutions %
info
38.34%
Analyst Insights & forecasts
info

86% Buy

0% Hold

14% Sell

Based on information from 7 analysts.

Average price target

info
$33.00
Earnings per share (EPS) forecast
windowbar_chart_4_bars
Actual
info
Expected
info
Surprise
info
-$0.15
-$0.21
28.57%
Q3 • 25Beat
-$0.27
-$0.49
44.90%
Q4 • 25Beat
-$0.33
-$0.23
-44.36%
Q1 • 26Current
QuarterlyAnnual
Financial Performance
windowbar_chart_4_bars
Income StatementBalance SheetCash Flow
windowbar_chart_4_bars
Revenue
info
Net income
info
Profit margin
info
$0.4M
$-14.9M
-3,544.32%
Q1 • 26
$-12.3M
0.00%
Q2 • 26
NaN%
-17.69%
0.00%
QoQ growth
QuarterlyAnnual
Totals assets
info
Total liabilities
info
Debt to assets
info
$115M
$65.7M
57.09%
Q1 • 26
$106M
$67.9M
63.85%
Q2 • 26
-7.57%
3.38%
11.84%
QoQ growth
QuarterlyAnnual
Operating
info
Investing
info
Financing
info
Free cash flow
info
$-15.6M
$10M
$0M
$-15.6M
Q1 • 26
$1.5M
-
$0M
$1.5M
Q2 • 26
-109.58%
-
∞%
-109.58%
QoQ growth
QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Silence Therapeutics PLC share?
Collapse

Silence Therapeutics PLC shares are currently traded for undefined per share.

How many shares does Silence Therapeutics PLC have?
Collapse

Silence Therapeutics PLC currently has 62.2M shares.

Does Silence Therapeutics PLC pay dividends?
Collapse

No, Silence Therapeutics PLC doesn't pay dividends.

What is Silence Therapeutics PLC 52 week high?
Collapse

Silence Therapeutics PLC 52 week high is $17.58.

What is Silence Therapeutics PLC 52 week low?
Collapse

Silence Therapeutics PLC 52 week low is $4.19.

What is the 200-day moving average of Silence Therapeutics PLC?
Collapse

Silence Therapeutics PLC 200-day moving average is $7.56.

Who is Silence Therapeutics PLC CEO?
Collapse

The CEO of Silence Therapeutics PLC is Iain Gladstone Ross B.Sc., BSc (Hons), C.DIR, CH.D.

How many employees Silence Therapeutics PLC has?
Collapse

Silence Therapeutics PLC has 88 employees.

What is the market cap of Silence Therapeutics PLC?
Collapse

The market cap of Silence Therapeutics PLC is $919M.

What is the P/E of Silence Therapeutics PLC?
Collapse

The current P/E of Silence Therapeutics PLC is null.

What is the EPS of Silence Therapeutics PLC?
Collapse

The EPS of Silence Therapeutics PLC is -$1.30.

What is the PEG Ratio of Silence Therapeutics PLC?
Collapse

The PEG Ratio of Silence Therapeutics PLC is null.

What do analysts say about Silence Therapeutics PLC?
Collapse

According to the analysts Silence Therapeutics PLC is considered a buy.